Areas of Research
Office of the Vice President
Office of Intellectual Property & Commercialization
Office of Sponsored Projects
Compliance & Review Boards
Research Foundation
Forms & Downloads
Funding Opportunities
Policies & Procedures
Proposal Preparation
Resource Links
Routing Proposals
Training & Workshops
Travel FAQs
News Articles
Spotlight Articles
Breeze Newsletter
Events Calendar
Browse Projects
Browse People

A Microfluidic platform for Enhancing Methylglyoxal Detection in Type 1 Diabetic Brain Tissue

Description :  

Methylglyoxal (MG) is a highly reactive metabolite of glucose and a prominent marker of dicarbonyl stress is diabetes. Recent studies by Dr. Stokes’s lab implicate a role for MG in brain microvascular endothelial dysfunction, thrombosis, and increased infarct seen in type 1 diabetic mice following stroke. Given the importance of glycated proteins in diabetic pathology, Dr. Stokes’s work focuses on developing therapeutic strategies to decrease protein glycation in diabetes. Dr. Hollins’s lab has developed a microfluidic platform for selective capture of carbonylated proteins. The objective of this project is to use Dr. Hollins expertise in microfluidics to develop a microfluidic platform that enhances the analytical detection and measurement of methylglyoxal (MG)- glycated proteins in diabetic rodents tissues. We will develop the microfluidic enrichment platform and validate it using diabetic rodent tissues samples from Dr. Stokes’ research group. Key innovations for this project include the development of a microfluidic enrichment platform for MG-mediated protein adducts and the demonstration and biological application of two-dimensional carbonylated protein enrichment, a technique not possible with standard preconcentration approaches. The proposed research is timely and medically significant since diabetes is a leading and growing global health concern. Diabetic patients exhibit increased CVD risk, even with well-controlled blood sugar levels. Development of a method to enrich MG-glycated proteins for further analysis and allow for testing of the efficacy of therapeutic strategies designed to decrease this glycation could help reduce risk of stroke, myocardial infraction and other diabetic pathologies.  

Principal Investigator:  Hollins, Bryant  --  Biomedical Engineering
Funding Agencies:  LSU/PAC
Amount Awarded:  17,540

Start Period:  00/00/0000 End Period:  00/00/0000
Related People
No Affiliated People

October 17th, 2018

Browse Projects

Browse People

Recent Articles

2017 Annual Student Research Symposium...

More News...

Page Tools

Print Page      Email Page

Louisiana Tech University, A Member of the University of Louisiana System
2018 Louisiana Tech University P.O. Box 3178 Ruston, LA 71272